Nicole Sweeny Sells 1,861 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,861 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $49,837.58. Following the completion of the sale, the insider owned 55,780 shares of the company’s stock, valued at $1,493,788.40. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total value of $37,649.64.

KalVista Pharmaceuticals Trading Up 0.1%

NASDAQ KALV traded up $0.02 on Tuesday, reaching $26.81. The company had a trading volume of 8,068,030 shares, compared to its average volume of 7,414,539. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -7.75 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $26.85. The business has a 50 day moving average of $21.74 and a two-hundred day moving average of $17.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $39.17 million during the quarter, compared to analyst estimates of $39.03 million. Analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on KALV. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Stifel Nicolaus upped their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Hold” and an average target price of $30.60.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC boosted its position in KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 589 shares during the last quarter. Royal Bank of Canada boosted its position in shares of KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 1,686 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Finally, Truvestments Capital LLC grew its stake in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.